Travere Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Bay here from Travere Therapeutics for a fireside chat this afternoon. Maybe I'll kick it over to Eric for a brief overview of the company, and then we'll get into a Q&A.
Eric? Yeah, great. Alex, thanks so much for hosting us.
It's been a great day. I'm Eric, and Travere is a San Diego-based rare disease company. We are both commercial stage as well as development with our pipeline. We have been leading in many ways within the emerging rare kidney disease space, launching first within IgA nephropathy and now the first medicine approved for focal segmental glomerulosclerosis, or FSGS. Our focus has been very much within rare kidney disease, and we also have branched out into rare metabolic disease. Our focus has been in those areas that are of highest unmet need, where we believe that the emerging science allows us to translate that into hope and commercialization of our medicines.
Great. Yeah, I've lost track of time, but you've recently reported 3Q earnings, the second quarter now of FSGS, and continuation of IgAN for FILSPARI as well. Can you sort of talk at a high level about the quarter and some of the underlying dynamics there?
Yeah, absolutely. We're very proud to have another strong quarter. We had $200 million in revenue posted, and I think it reflects not just the underlying demand, but also a very strong base of continuing patients, particularly with IgA nephropathy. In the quarter, we received 1,932 new patient start forms, and I think it's easy for us to lose sight of the numbers. I think if we take a step back and say, "We have a medicine that is reaching nearly 2,000 patients in a quarter," when just a number of years ago, there was nothing for these communities. We're really proud of the impact that we've had. When we look at some of the underlying dynamics, and that can probably fill the- Sure remaining time that we have.
Yeah. I will cover the highlights.
The first is a very strong level of demand. The second is that we anticipated and talked about the summer seasonality that we have seen each year within the rare kidney disease space, particularly within IgA nephropathy. And we saw nearly identical rate of decrement in patient start forms, small low percentage in Q3 versus Q2, which is reflective of the lower number of patient visits to nephrologists that we see in audited chart data for patient visits. And that was the same that we saw in 2025 as well as 2024. There were some slight adjustments around that for FSGS, where we saw numerically more Sure versus Q2, and in IgA nephropathy, we saw slightly less than what we saw in Q2, but largely a very, very strong quarter of demand.
So maybe starting with IgAN, as you alluded to, you saw the seasonality last year. But I think one of the questions that folks are trying to wrestle with here, and I think you talked about this on the call as well, is with the ongoing launches of sibeprenlimab and atacicept, there is this question around, is this truly a seasonality or is this a shift in the way that nephrologists are thinking about treating IgAN now that we have these other drugs?
Yeah. How are you thinking about that as an underlying trend?
Yeah. What I would say is that in large part, this is about seasonality.
Yep. I think that if we look at what the data and the patterns actually show, it's more seasonality.
Now, we do not see any evidence in the data, in the market research, or in the prescriptions that we see where there is a trade-off that physicians are making to say, "I'm going to now shift away from FILSPARI and to the emerging B-cell class." What we are seeing, however, are nephrologists now having six, seven new companies talk to them, which is a limitation on their time, a limitation on their attention. And we do fully expect to see continued positioning and strength of FILSPARI, and that's exactly what we're hearing from nephrologists when we meet with them around our advisory work as well as market research. There is going to be a lot of dynamism.
Yeah. But I see dynamism as a real lead measure of growth in this market as we see more patients being treated.
Yeah More patients being treated earlier.
Yeah. Can you talk a little about, I guess, the KDIGO guidelines specifically and how is there a path for you to sort of really cement FILSPARI as a combination drug on top of or with a BAFF/APRIL? How is that going to play out, and how are you working towards getting that to play out?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
